Elad Sharon: I am ecstatic to announce that I am joining Dana-Farber as the Clinical and Translational Director of the iTOX Service.
Quoting Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, on X/Twitter:
”I am ecstatic to announce that I am joining Dana-Farber as the Clinical and Translational Director of the iTOX Service. I am proud of all we have been able to accomplish for patients utilizing the tools of immunotherapy from my time National Cancer Institute & I will continue drug dev efforts!
Monica M. Bertagnolli is an exceptional leader! Collaboratively with NCI Center for Cancer Research, NCI CTEP Clinical Research, NCI Cancer Stats & others, I hope I can continue to contribute to this incredible field with my academic, pharmaceutical, FDA Oncology, and National Cancer Institute colleagues!
We are in an amazing time for cancer research and innovation. To reach cancer moonshots, cancer ground shots & more, we must redouble our efforts, we must leave no patients behind and we must learn from every patient and every experience!
My incredible colleagues from Dana-Farber have been so supportive in this transition! I feel lucky to be joining this group and I feel we can achieve great things together!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023